Asset
BEMPEGALDESLEUKIN
Nektar Therapeutics Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02869295 | phase1_2 | completed | 2015-12-01 | 2018-10-31 | Nektar Therapeutics | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
| NCT03138889 | phase1_2 | terminated | 2017-06-09 | 2022-07-05 | Nektar Therapeutics | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.